BioStock: Immunicum finalises phase I ILIAD trial

Immunicum’s phase Ib ILIAD project was designed to evaluate ilixadencel across a broad range of cancer indications and in combination with the anti-PD1 checkpoint inhibitor pembrolizumab. The company has announced completing the project after conducting a positive safety and response evaluation, and Immunicum has decided not to pursue a phase II portion of the trial. BioStock spoke with CEO Erik Manting to learn more about the results and the decision-making around phase II.

Read the interview with Immunicum's CEO Erik Manting at biostock.se:

https://www.biostock.se/en/2021/12/immunicum-finalises-phase-i-iliad-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se